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SUMMARY – Renal sympathetic denervation (RSD) could be an effective antihypertensive 
treatment of resistant hypertension that triggers additional positive effects on glucose metabolism 
and insulin sensitivity in type 2 diabetes mellitus. We report the effects of RSD in a patient with 
chronic kidney disease, type 2 diabetes mellitus and resistant hypertension, manifesting as blood 
pressure reduction with dipping pattern restoration, followed by nephrotic proteinuria alleviation. 
The non-dipping blood pressure pattern and proteinuria increase the risk of cardiovascular compli-
cations and accelerate kidney disease progression. Thus, further research documenting the frequency 
and investigating the mechanisms of these effects reported after RSD in chronic kidney disease 
patients with type 2 diabetes mellitus and resistant hypertension is necessary for the benefit of this 
high-risk patient population.
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Introduction
Diabetic nephropathy is characterized by hyperten-
sion, albuminuria (macroalbuminuria/proteinuria) and 
progressive loss of renal function. The available data 
suggest that afferent signals from affected kidneys to 
integrative structures in the brain result in chronic el-
evation of sympathetic outflow. Increased sympathetic 
activity inducing vasoconstriction, renin-angiotensin-
aldosterone system (RAAS) activation, sodium and 
fluid reapportion and proteinuria plays an important 
role in the aggravation of hypertension and further de-
terioration of renal function1. Therefore, pharmacologi-
cal inhibition of the sympathetic nervous system with 
lowering blood pressure and/or RAAS activity reduc-
tion through proteinuria alleviation exerts renoprotec-
tive effect in type 2 diabetic (T2DM) patients with 
hypertension and chronic kidney disease (CKD)2-5. 
Although frequently used in such patient populations, 
pharmacological inhibitors do not provide adequate 
antihypertensive or renoprotective effect in clinical 
practice6. Renal sympathetic denervation (RSD) as 
endovascular catheter-based intervention by providing 
multilevel inhibition of the sympathetic nervous system 
could be an appealing concomitant therapeutic option 
for treating resistant hypertension in patients with dia-
betic nephropathy and CKD7.
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Case Report
Here we describe a case of a 57-year-old male with 
diabetic nephropathy and CKD stage 3, submitted to 
RSD due to severe hypertension resistant to treatment 
with seven antihypertensive drugs from different 
(complementary) drug classes including an appropri-
ately dosed diuretic. These drugs were: 10 mg ramipril 
qd (angiotensin-converting enzyme inhibitor), 40 
mg nifedipine delayed-release bid (calcium chan-
nel blocker), 90 mg urapidil bid (direct vasodilator), 
10 mg torsemide qd (diuretic), 320 mg valsartan qd 
(angiotensin receptor blocker), 0.6 mg in the evening 
moxonidine (centrally acting sympatholytic) and 50 
mg spironolactone qd dose (aldosterone antagonist).
Before the intervention, antihypertensive treat-
ment was optimized according to the BHS/NICE 
treatment algorithm adapted from CG127; non-con-
cordance with pharmacotherapy as well as secondary 
forms of hypertension were excluded. The patient had 
had T2DM for seven years and was educated on self-
management and treated with oral antidiabetic agents 
(OADs). In 2010, the patient was diagnosed with dia-
betic nephropathy based on increased urinary albu-
min excretion (UAE), with no hematuria and normal 
kidney ultrasound dimensions. Three months prior to 
RSD, the creatinine-based estimated glomerular fil-
tration rate (eGFR) decreased to <60 mL/min/1.73m2 
and OADs therapy (metformin and glimepiride) was 
replaced with the insulin secretagogue gliquidone, 30 
mg bid. 
The RSD treatment method and its potential risks 
and benefits were explained to the patient and his writ-
ten consent was obtained. RSD was performed with 
standard radiofrequency delivery system with ablation 
catheter (5F system/6F guide catheter; SymplicityTM 
RDN System, Medtronic Inc., Mountain View, CA, 
USA) inserted through the femoral artery. Addition-
ally, multiple three-dimensional imaging and catheter 
monitoring were used to precisely pinpoint the sites 
of radiofrequency energy delivery, engaging the renal 
artery bilaterally. Five nerve ablations on each side 
were performed. The RSD procedure was completed 
without any complications. The 24-hour ambula-
tory blood pressure monitoring (ABPM), medication 
therapy and laboratory analysis were assessed at base-
line (before RSD), and at 1-, 3- and 6-month follow 
up visits. 
The ABPM data were divided into 3 eight-hour 
segments: morning (06.00-14.00 h), afternoon (14.00-
22.00 h) and sleep-time (22.00-06.00 h). The mean 
arterial pressure (MAP = [(2 x diastolic) + systolic]/3) 
was calculated for each segment and expressed as mean 
± standard deviation (SD). Comparison of two means 
was performed using the Student’s t-test. Comparison 
of several means was performed using two-way (two 
factors tested) analysis of variance and the Newman-
Keuls post hoc test. Changes between the baseline and 
consecutive follow up visits within the same eight-
hour segment were considered statistically significant 
if p<0.001 (two-tailed). Statistical analysis was per-
Table 1. Blood pressure and renal function before and after renal sympathetic denervation
Parameter Before RSD After RSD1 month 3 months 6 months
Systolic ABPM (mm Hg) 198±24 172±20 174±17 178±16
Diastolic ABPM (mm Hg) 92±14 85±18 85±24 67±8
Heart rate (bpm) 74±8 74±11 74±20 60±6
Night/day ratio of MAP 1.11 0.85 0.86 0.86
Serum creatinine (mol/L) 154 174 217 171
eGFR (mL/min/1.73m²) 39 35 32 33
Urinary protein (mg/day) 4605 1900 554 591
Urinary albumin (mg/day) 4325 1798 458 442
RSD = renal sympathetic denervation; ABPM = ambulatory blood pressure measurements (24-hour); eGFR (MDRD) = excretion 
glomerular filtration rate; MAP = mean arterial pressure; ABPM and heart rate values are expressed as mean  standard deviation (SD); 
other data are presented as number.
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formed using the STATISTICA 10, 2011 software 
(Stat Soft Inc., Tulsa, OK, USA). 
The ABPM at baseline revealed hypertension with 
non-dipping BP pattern before RSD. The RSD 
significantly decreased MAP at month 1, 3 and 
6 (100.8±11.4 mm Hg; 101.6±10.5 mm Hg; and 
92.1±11.9 mm Hg, respectively) compared to base-
line (137.2±16.5 mm Hg), significantly decreased 
morning MAP at month 1 and 6, and restored 
the dipping BP pattern (circadian blood pressure 
rhythm) (Fig. 1). An additional positive effect of 
RSD on nephrotic proteinuria alleviation was ob-
served (Table 1), with better control of diabetes 
(HbA1c 7.1% before RSD, 6.8% at 3 months after 
RSD and 6.9% at 6 months after RSD). Moreover, 
we observed 87% serum renin reduction 6 months 
after RSD compared to baseline. Antihypertensive 
drug treatment dose and regimen remained the 
same throughout the 6-month period. There were 
no changes in antidiabetic treatment. 
Discussion
To the best of our knowledge, this is the first case 
report of a CKD patient with nephropathy and resis-
tant hypertension having limiting effect on BP level 
optimization, but circadian rhythm restoration and 
nephrotic proteinuria alleviation after RSD treat-
ment. Neither the Symplicity Trials nor the European 
Society of Cardiology Recommendations find CKD 
patients with eGFR 45 mL/min/1.73m² and resistant 
hypertension to be eligible for RSD treatment8. How-
ever, individual data show antihypertensive effects of 
RSD intervention in CKD patients with eGFR 45 
mL/min/1.73m² and resistant hypertension9.
Normal circadian BP rhythm includes nocturnal 
BP decline, i.e. the dipping BP pattern (more than 
10% sleep-time relative BP decline). In T2DM pa-
tients, the non-dipping pattern is highly correlated 
with the rate of albumin excretion; 80% of T2DM pa-
tients with albuminuria A3 (macroalbuminuria) were 
found to have loss of sleep-time BP decline10. The 
non-dipping BP pattern was demonstrated to be relat-
ed to a more prominent failure to respond to antihy-
pertensive medication11. Moreover, it accelerates kid-
ney disease progression to end-stage renal failure and 
increases the risk of cardiovascular complications10,11. 
Therefore, RSD elicited sleep-time BP decline is ex-
pected to have multiple long term benefits. In addi-
tion, proteinuria alleviation after RSD intervention 
is an important observation. Proteinuria is an inde-
pendent risk factor for kidney disease progression and 
recognition of the antiproteinuric treatment is essen-
tial for providing renoprotection12.
Further research documenting the frequency and 
investigating the mechanisms of these effects reported 
after RSD in CKD patients with T2DM and resis-
tant hypertension is necessary, as RSD may constitute 
an effective treatment option to reduce cardiovascular 
risk and kidney failure progression.
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RSD = renal sympathetic denervation; BS = baseline (before 
RSD); MAP = mean arterial pressure; 1 = 1-month follow 
up visit, 3 = 3-month follow up visit; 6 = 6-month follow up 
visit; MAP values are mean ± SD; *statistically significant 
difference (p<0.001). 
Fig. 1. Circadian blood pressure rhythm before and 
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Sažetak
POBOLJŠANJE KRVNOG TLAKA, CIRKADIJALNOG RITMA I PROTEINURIJE U BOLESNIKA S 
KRONIČNOM BUBREŽNOM BOLEŠĆU NAKON POSTUPKA DENERVACIJE BUBREŽNIH ARTERIJA 
I. Prkačin, V. Ćorić-Martinović, T. Bulum, G. Cavrić, V. Đermanović-Dobrota i V. Vidjak
Denervacija bubrežnih arterija (DBA) je jedna od obećavajućih novih metoda liječenja rezistentne hipertenzije re-
fraktorne na optimalno liječenje kombiniranom antihipertenzivnom terapijom koja uključuje 3 i više lijekova iz različitih 
antihipertenzivnih skupina, od kojih jedan mora biti diuretik. Uz učinak na sniženje tlaka, radiofrekventnom ablacijom 
periarterijskih simpatičkih niti denervacijom uočeni su dodatni pleotropni pozitivni učinci poput regulacije glikemije i 
inzulinske rezistencije u osoba sa šećernom bolešću tipa 2. U radu je prikazan učinak DBA u bolesnika s kroničnom bu-
brežnom bolešću (KBB), šećernom bolešću tipa 2 i refraktornom hipertenzijom: djelomično sniženje krvnog tlaka polučilo 
je dodatni učinak na snižavanje krvnog tlaka tijekom noći uz smanjenje nefrotičke proteinurije, bez pogoršanja KBB. Izo-
stanak očekivanog sniženja krvnog tlaka tijekom noći i nefrotska proteinurija povećavaju kardiovaskularni rizik bolesnika i 
progresiju KBB. Daljnja prospektivna istraživanja mehanizama nastanka povoljnih učinaka DBA u bolesnika sa šećernom 
bolešću tipa 2, KBB i rezistentnom hipertenzijom su neophodna kako bi se dokazali dodatni učinci blokade simpatičkog 
sustava DBA u ove visoko rizične populacije.
Ključne riječi: Cirkadijalni ritam; Dijabetička nefropatija; Proteinurija; Hipertenzija – farmakoterapija; Bubreg – inervaci-
ja; Simpatektomija – metode; Prikazi slučaja
